Clinical Trial Update: Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating semaglutide for reducing arrhythmia burden in overweight patients with atrial fibrillation has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Obesity

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: Axel Brandes | Conditions: Atrial Fibrillation, Overweight and Obesity | Phase 3 | Status: WITHDRAWN